An Unusual Introduction to Practice

Por Menzies, A. M.
Publicado em 1959

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

Por Menzies, A M, Wilmott, J S, Long, G V, Scolyer, R A
Publicado em 2014

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

Por Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A., Wang, T. W., Carlino, M. S., Hong, A., Long, G. V.
Publicado no Oncoimmunology (2016)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma

Por Wilmott, J S, Menzies, A M, Haydu, L E, Capper, D, Preusser, M, Zhang, Y E, Thompson, J F, Kefford, R F, von Deimling, A, Scolyer, R A, Long, G V
Publicado em 2013

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Por Pollack, M H, Betof, A, Dearden, H, Rapazzo, K, Valentine, I, Brohl, A S, Ancell, K K, Long, G V, Menzies, A M, Eroglu, Z, Johnson, D B, Shoushtari, A N
Publicado no Ann Oncol (2018)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

Por Carlino, M S, Haydu, L E, Kakavand, H, Menzies, A M, Hamilton, A L, Yu, B, Ng, C C, Cooper, W A, Thompson, J F, Kefford, R F, O'Toole, S A, Scolyer, R A, Long, G V
Publicado em 2014

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

Por Tetzlaff, M T, Messina, J L, Stein, J E, Xu, X, Amaria, R N, Blank, C U, van de Wiel, B A, Ferguson, P M, Rawson, R V, Ross, M I, Spillane, A J, Gershenwald, J E, Saw, R P M, van Akkooi, A C J, van Houdt, W J, Mitchell, T C, Menzies, A M, Long, G V, Wargo, J A, Davies, M A, Prieto, V G, Taube, J M, Scolyer, R A
Publicado no Ann Oncol (2018)